Sexually transmitted infections (STIs) are among the most common infectious conditions globally, with the CDC estimating nearly 26 million new STI cases annually in the United States. Most STIs cause no symptoms in their early stages, making routine screening the only reliable way to identify and treat them before they cause long-term complications (PID, infertility, chronic pain, cancer) or unknowing transmission to partners. Medical clinics provide confidential, comprehensive STI screening appropriate to each patient’s specific risk profile. This guide explains what STI screening involves at the clinical level.
Common STIs and Their Tests
Chlamydia and Gonorrhea
Nucleic acid amplification tests (NAATs) on urine or genital swab samples detect chlamydia and gonorrhea with high sensitivity. The CDC recommends annual chlamydia and gonorrhea screening for all sexually active women under 25, and for older women and men with increased risk factors. Extragenital screening (throat, rectal swabs) is appropriate for patients with relevant exposures.
Syphilis
Blood tests (VDRL or RPR, confirmed by treponemal antibody tests) detect syphilis. Syphilis rates have increased dramatically in the United States in recent years — screening is recommended for sexually active MSM (men who have sex with men), pregnant women, and others at risk.
HIV
4th generation combination antigen/antibody tests detect HIV as early as 18–45 days after infection. Universal once-per-lifetime screening is recommended for all adults; annual screening for those at ongoing risk. Point-of-care rapid HIV tests provide results in 20 minutes at clinic visits.
Herpes (HSV)
Herpes simplex virus (HSV-1 and HSV-2) blood testing identifies antibodies to herpes but cannot determine site of infection, when infection occurred, or whether sores will develop. Clinical diagnosis of herpes lesions through viral culture or PCR swabbing of active sores is more meaningful. Routine HSV blood testing in asymptomatic individuals without known exposure is generally not recommended.
Comprehensive STI Screening Visit
A comprehensive STI screen typically includes tests for chlamydia, gonorrhea, syphilis, HIV, and hepatitis B and C. Depending on sexual practices and exposures, additional testing (extragenital swabs, hepatitis A, HPV assessment) may be added. Clinics provide risk-based screening rather than a single protocol for all patients.
Conclusion
STI screening is a routine component of sexual health care — not a reflection of behavior judgment. Regular, appropriate screening protects your health and the health of your partners. Tell your clinician honestly about your sexual practices and risk factors so they can recommend the most appropriate testing for your specific situation.
FAQs – STI Screening
Q1. How often should I be screened for STIs?
A: Frequency depends on your specific risk profile. Sexually active women under 25 and all MSM should be screened at least annually for chlamydia and gonorrhea. HIV screening depends on ongoing risk. Discuss your personal risk with your clinic for individualized guidance.
Q2. Is STI screening confidential?
A: Yes, with a specific exception: positive results for certain STIs (HIV, syphilis, gonorrhea, chlamydia, and others) are mandated to be reported to state health departments for public health surveillance. Your personal identity is protected in this reporting, and partners may be notified through partner services programs.
Q3. Can I get tested for STIs without my parents knowing if I am a minor?
A: In most states, minors can consent to STI testing and treatment without parental consent. Laws vary by state — call your local clinic or health department to confirm the rules in your state.
Q4. What STIs can be cured?
A: Bacterial STIs (chlamydia, gonorrhea, syphilis) are curable with antibiotics. Viral STIs (HIV, herpes, hepatitis B) are manageable but not currently curable. HPV has no specific treatment — most infections clear spontaneously, and vaccination prevents the most important strains.
Q5. What is PrEP and who should take it?
A: Pre-exposure prophylaxis (PrEP) — daily oral medication (Truvada or Descovy) or bimonthly injectable cabotegravir — reduces HIV transmission risk by over 99% in adherent individuals at ongoing HIV exposure risk. Clinics prescribe PrEP after an initial assessment including HIV testing, kidney function, and STI screening.
